Net Income

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

Chinese data center giant VNET promotes Peter Zhang to SVP, signaling a focus on stability and governance as it navigates rapid AI-driven growth.

The Canadian restaurant giant defied a tough market in 2025, posting record sales and boosting investor payouts through strategic promotions and delivery.

Comparor launches its AI assistant, joining a tech race to simplify shopping and find the best price. But what does this mean for you and for retailers?

The uranium giant posted a massive jump in 2025 earnings, fueled by strategic investments and a global rush for clean, secure energy. Here's what's next.

A Taiwanese whisky distributor is betting big on AI with $120M in proposed deals, raising questions of genius, risk, and the frenzy of the AI gold rush.

Applied Optoelectronics breaks ground on a massive Texas facility, aiming to secure the domestic supply chain for the critical components powering America's AI boom.

The pipeline giant's record $20B EBITDA is fueled by traditional energy, while it aggressively expands into renewables to power the digital economy.

Essent Group boosts its dividend after a strong 2025, returning $700M to shareholders while making a strategic leap into the global P&C reinsurance market.

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

A new 'Wuthering Heights' film arrives, but its true story may be its surprising link to the global phenomenon of the telenovela. How did it happen?

With a top Hong Kong director and stars on the NBA stage and Disney+, Catwalk Entertainment is building a content empire to take Mandarin media global.

Legrand's plan to repurchase 250,000 shares goes beyond pure financials, signaling a strategic investment in its workforce amid a competitive market.

Capgemini's 2025 results show a strong pivot to AI, with bookings soaring and a €700M plan to reshape its workforce for a new era of tech.

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

Fermi America's plan to revive nuclear power for AI's energy needs with a massive Texas campus faces past industry failures and new legal scrutiny.

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

Home prices see modest gains, but rising incomes and balanced inventory are shifting the power back to homebuyers for the first time since the pandemic.

Vitalist reports soaring losses and a $6.4M debt surge, raising 'going concern' alarms. Can its new Reebok smartwatches and VitalOS™ platform save it?